Key result
PDHA1 deficiency in human iPSC-derived cardiomyocytes induces myocardial hypertrophy and heart failure phenotypes via decreased energy production and calcium homeostasis imbalance.
Why the study?
PDHA1 is reduced in hypertrophic cardiomyopathy patients and its deficiency causes hypertrophy in mice, but underlying pathogenic mechanisms remain unclear.
Does PDHA1 deficiency induce myocardial hypertrophy in human iPSC-CMs, and can l-carnitine prevent these effects?
Does PDHA1 deficiency induce myocardial hypertrophy in human iPSC-CMs, and can l-carnitine prevent these effects?
Answers are grounded in this paper and cite their sources.
PDHA1 deficiency induces myocardial hypertrophy in human cardiomyocytes through energy depletion and calcium imbalance, a process that can be mitigated by l-carnitine supplementation.
The PDHA1 gene, responsible for regulating the conversion of the glycolytic product pyruvate to acetyl CoA, is significantly reduced in cardiomyocytes of patients with hypertrophic cardiomyopathy. Cardiac-specific PDHA1-deficient mice demonstrate cardiac hypertrophy and heart failure. However, the mechanisms underlying the pathogenesis of PDHA1 deficiency remain unclear. PDHA1 gene in human induced pluripotent stem cell line (iPSC) was knockout (KO) using CRISPR-Cas9 technology and differentiated it into cardiomyocytes (CMs) in vitro. Contractile force was quantified by video analysis, Ca 2+ handling was assessed with Ca 2+ transient analysis and mitochondrial function was detected using flow cytometry. The PDHA1 KO iPSC-CMs displayed myocardial hypertrophy phenotypes by day 40 post-differentiation, characterized by enlarged cell size, increased contractility, abnormal calcium handling, and progressed to mimic heart failure phenotypes by day 50, including reduced contractility, lower calcium release and increased ROS generation. RNA-seq analysis revealed dysregulated expression of pathways related to cardiac hypertrophy and the calcium signaling pathway in KO iPSC-CMs. Furthermore, KO iPSC-CMs exhibited decreased energy production before the manifestation of myocardial hypertrophic phenotype at day 30, exacerbating intracellular lactate accumulation, leading to increased sodium‑hydrogen and sodium‑calcium exchange, ultimately resulting in elevated diastolic calcium concentration. Augmenting energy production with l -carnitine restored diastolic Ca 2+ and prevented the development of myocardial hypertrophy in KO iPSC-CMs. Elevated diastolic Ca 2+ resulting from reduced energy production and lactate accumulation can trigger overactivation of the calcium signaling pathway, diastolic dysfunction, mitochondrial damage, which constitutes the core pathogenic mechanism of myocardial hypertrophy in KO iPSC-CMs. • PDHA1 deficiency leads to myocardial hypertrophy in human cardiomyocytes • Increased diastolic calcium concentration in PDHA1 deficiency cardiomyocytes is closely related to the elevated intracellular lactate concentration • Decreased energy production exacerbates the disruption of calcium homeostasis and the increase in lactate concentration • l -carnitine improves myocardial hypertrophy caused by PDHA1 deficiency by increasing energy production
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied Myocardial hypertrophy. PDHA1 knockout vs. Wild-type cells was evaluated on Myocardial hypertrophy phenotypes (cell size, contractility, calcium handling). PDHA1 deficiency in human iPSC-derived cardiomyocytes induces myocardial hypertrophy and heart failure phenotypes via decreased energy production and calcium homeostasis imbalance.
Synapse has enriched 10 related papers. Consider them for comparative context: